CapsoVision, Inc.’s Lock-Up Period Set To End on December 29th (NASDAQ:CV)

CapsoVision’s (NASDAQ:CV) lock-up period will expire on Monday, December 29th. CapsoVision had issued 5,500,000 shares in its initial public offering on July 2nd. The total size of the offering was $27,500,000 based on an initial share price of $5.00. After the expiration of CapsoVision’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Roth Capital set a $7.00 target price on shares of CapsoVision in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (e)” rating on shares of CapsoVision in a research report on Monday, December 15th. Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. Finally, Zacks Research raised CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.00.

CapsoVision Stock Performance

Shares of CV stock opened at $13.23 on Monday. The business has a fifty day moving average of $6.48. CapsoVision has a 52 week low of $3.43 and a 52 week high of $15.37.

CapsoVision (NASDAQ:CV) last issued its earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $3.54 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new stake in CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.